Syndax Pharmaceuticals Inc ($SNDX)
Filing Information
| Accession Number | 0001193125-26-269694 |
|---|---|
| Form Type | 4 |
| Filing Date | Jun 12, 2026 |
| Document | View SEC Filing |
Transactions
6
Total Shares
173,015
Total Value
$1,926,467.90
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Head of R&D, CMO | Common Stock | โ | Jun 11, 2026 | Exercise/Conversion | 22,515 | $13.82 | $311,157.30 | 95,165 | Direct | โ | View Details | |
Head of R&D, CMO | Common Stock | โ | Jun 11, 2026 | Sale | 34,280 | $18.00 | $617,040.00 | 60,885 | Direct | โ | View Details | |
Head of R&D, CMO | Common Stock | โ | Jun 12, 2026 | Exercise/Conversion | 31,235 | $13.82 | $431,667.70 | 92,120 | Direct | โ | View Details | |
Head of R&D, CMO | Common Stock | โ | Jun 12, 2026 | Sale | 31,235 | $18.14 | $566,602.90 | 60,885 | Direct | โ | View Details | |
Head of R&D, CMO | Stock options (Right to buy) | Derivative | Jun 11, 2026 | Exercise/Conversion | 22,515 | $0.00 | $0.00 | 0 | Direct | โ | View Details | |
Head of R&D, CMO | Stock options (Right to buy) | Derivative | Jun 12, 2026 | Exercise/Conversion | 31,235 | $0.00 | $0.00 | 0 | Direct | โ | View Details |